Company Focus
Alnylam Pharmaceuticals
Latest Alnylam Pharmaceuticals News
Biotechnology
RNAi therapeutics company Alnylam Pharmaceuticals has announced the planned expansion of its manufacturing facility in Norton, Massachusetts. 18 December 2025
Related News
Insights
Company Spotlight
A privately held biotechnology platform company based in the Boston, Massachusetts area. It operates as a partner-facing “ecosystem” business supporting biologics discovery and development across multiple modalities, and it also participates in company creation through its venture studio model.
Latest News & Features of interest to Alnylam Pharmaceuticals
Biotechnology
Netherlands-based Scenic Biotech, a company advancing modifier therapy—a radical new approach to treating genetic disorders—has announced another collaboration with a major pharma company. 7 January 2026
Pharmaceutical
Swiss anti-infectives specialist Basilea has struck a research collaboration with US biotech Prokaryotics to develop a first-in-class, broad-spectrum antifungal aimed at severe invasive infections. 7 January 2026
Biotechnology
New York-based clinical-stage biotech LB Pharmaceuticals had announced the appointments of Ellen Rose as senior vice president, corporate affairs and Lindsay Beaupre as SVP people and culture. 7 January 2026
Biotechnology
Artis BioSolutions, a San Diego, USA-based advanced-therapies development and manufacturing company that launched in April this year, today announced that it has entered into a definitive agreement to acquire Syngoi Technologies, a Spanish biotechnology company pioneering novel enzymatic approaches for manufacturing synthetic DNA technologies. 6 January 2026
Pharmaceutical
Switzerland-based Oculis Holding has announced that its neuroprotective candidate privosegtor was granted breakthrough therapy designation by the US Food and Drug Administration (FDA) for treatment of optic neuritis (ON). 6 January 2026
Pharmaceutical
The US Department of Health and Human Services has announced a sweeping revision to the childhood vaccination schedule, sharply reducing the number of shots recommended for all children and moving closer to Denmark’s approach. The shift replaces a single universal policy with a tiered framework. 6 January 2026
Biotechnology
Chris Murphy has been appointed chief executive of privately-held US genetic medicines company, ElevateBio, also joining its board of directors. 5 January 2026
Generics
Taiwanese drugmaker ScinoPharm has secured approval from the US Food and Drug Administration for its glatiramer acetate injection, a generic treatment for multiple sclerosis. The company said it is the first pharmaceutical group in Taiwan to obtain US clearance for this complex injectable product. 5 January 2026
Pharmaceutical
Swiss pharma Idorsia saw its shares rise 8% to 4.60 francs in early trading today after it announced that Health Canada has granted marketing authorization for Jeraygo (aprocitentan). 5 January 2026
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Kostaive (zapomeran) mRNA COVID-19 vaccine, for the immunization of individuals aged 18 years of age and older. 2 January 2026
Latest In Brief for Alnylam Pharmaceuticals
Pharmaceutical
French pharma major Sanofi is preparing an offer to acquire the US biopharmaceutical firm Ocular Therapeutix, according to a report by French publication La Lettre. 16 January 2026
Latest Relevant Ones To Watch News
Hong Kong-listed Sino Biopharmaceutical is to buy fellow Chinese firm Hangzhou Hygieia Biomedical. 13 January 2026
8 January 2026
6 January 2026
22 December 2025
12 December 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze